By Myles Starr
High demand and short supply of medications known as GLP-1 (glucagon-like peptide-1) antagonists used to treat diabetes and obesity have led many people desperate for these drugs to online marketplaces that operate further from scrutiny than brick-and-mortar retail pharmacies. Consequently, the FDA is taking steps to stem the illicit trade in unapproved, mislabeled and sometimes harmful drugs offered by these retailers.
The agency sent warning letters on Oct. 2, 2023, to two